University of Oklahoma
ouhsc.eduTotal trials
416
Active
114
Phase 3
17
Total enrollment
46,148
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 57 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| nicotine patch | — | — | — | 5 | |||
| Nicotinamide riboside | — | — | — | — | 2 | ||
| Ketamine | — | — | — | — | — | 1 | |
| Meloxicam 7.5 mg | — | — | — | — | — | 1 | |
| Meloxicam 15 mg | — | — | — | — | — | 1 | |
| Acetaminophen 500mg | — | — | — | — | — | 1 | |
| Propranolol | — | — | — | — | — | 1 | |
| Fluconazole 150 mg | — | — | — | — | — | 1 | |
| Intranasal Midazolam | — | — | — | — | — | 1 | |
| Intranasal Dexmedetomidine | — | — | — | — | — | 1 | |
| Intranasal Ketamine | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Dapagliflozin 10Mg Tab | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 3 | ||
| QuitGuide + NRT | — | — | — | — | 2 | ||
| Bevacizumab | — | — | — | — | — | 5 | |
| Niraparib | — | — | — | — | — | 3 | |
| Varenicline | — | — | — | — | — | 2 | |
| Azithromycin | — | — | — | — | 2 | ||
| Pembrolizumab & Enfortumab Vedotin | — | — | — | — | — | 1 | |
| Disulfiram | — | — | — | — | — | 1 | |
| Smart-T Mental Health and NRT | — | — | — | — | — | 1 | |
| Smart-T Mental Health+ and NRT | — | — | — | — | — | 1 | |
| dostarlimab | — | — | — | — | — | 1 | |
| Echothiophate Iodide 0.125% Ophthalmic Solution | — | — | — | — | — | 1 | |
| nab-Sirolimus | — | — | — | — | — | 1 | |
| Fulvestrant | — | — | — | — | — | 1 | |
| Ketamine Topical | — | — | — | — | — | 1 | |
| Avutometinib (VS-6766) + defactinib | — | — | — | — | — | 1 | |
| Nicotine lozenge | — | — | — | — | — | 1 | |
| TPST-1495 | — | — | — | — | — | 1 | |
| Pebrolizumab + QUADSHOT Radiotherapy | — | — | — | — | — | 1 | |
| Cemiplimab 350 MG Intravenous Solution | — | — | — | — | — | 1 | |
| Fianlimab 1600 MG Intravenous Solution | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | 3 | ||
| Avelumab | — | — | — | — | 2 | ||
| AVB-S6-500 | — | — | — | — | — | 1 | |
| OK-1 | — | — | — | — | — | 1 | |
| FLT imaging and TK1 blood measurements | — | — | — | — | — | 1 |
17 more active programs hidden
Next readouts
- 2020-12-23
- 2022-04-07
- 2022-05-06
- 2024-12
- 2025-05
- 2025-05-31
- 2025-08-22
- 2025-09-25
- 2025-10-14
- 2026-01-06
Top conditions
- Smoking Cessation20
- Atrial Fibrillation10
- Obesity9
- Healthy8
- Endometrial Cancer8
- Cigarette Smoking7
- Peripheral Artery Disease7
- Health Behavior6
Frequently asked questions about University of Oklahoma
- How many clinical trials does University of Oklahoma have on ClinicalTrials.gov?
- University of Oklahoma is listed as the lead sponsor on 416 clinical trials in ClinicalTrials.gov, 114 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Oklahoma's trials are in Phase 3?
- 17 of University of Oklahoma's trials are in Phase 3, spread across 57 active drug programs.
- What therapeutic areas does University of Oklahoma focus on?
- University of Oklahoma's most-studied conditions on ClinicalTrials.gov are Smoking Cessation, Atrial Fibrillation, Obesity, Healthy, Endometrial Cancer.
- When are University of Oklahoma's next clinical trial readouts?
- University of Oklahoma has 10 upcoming primary-completion readouts tracked here; the soonest is “OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma”, expected around 2020-12-23.